
Aeovian Pharmaceuticals: Innovating treatments for rare and age-related diseases since 2012.
Founded in 2012, Aeovian Pharmaceuticals is a biopharmaceutical company based in the San Francisco Bay Area. The company's core mission is to discover, develop, and commercialize innovative therapeutics for treating rare and age-related diseases. Aeovian focuses on developing compounds that modulate molecular pathways to address the underlying causes of disease initiation and progression, such as oxidative, cellular, and environmental stress. Their lead development candidate, AV078, is currently in Phase clinical trials for treating seizures associated with Tuberous Sclerosis Complex (TSC).
Notable figures affiliated with Aeovian Pharmaceuticals include William Greene, MD, CIO at Hevolution, and Justin Gover, former CEO at GW Pharmaceuticals, both of whom have joined the board. The company has achieved significant milestones, including dosing the first cohort of participants in their Phase clinical trial and securing additional financing. Aeovian's innovative approach and strategic leadership have positioned it as a promising player in the biopharmaceutical industry, with a focus on impactful treatments for underserved patient populations.

Azevan Pharmaceuticals
azevan.com

Avalyn Pharma
avalynpharma.com

Aria Pharmaceuticals

Abvc Biopharma

Aether Therapeutics

Apexian Pharmaceuticals
apexianpharma.com

Aquavit Pharmaceuticals
aquavitpharma.com

Avior Bio

Gerostate Alpha

Aurion Biotech
aurionbiotech.com

Aquinnah Pharmaceuticals
aquinnahpharma.com

Navitor Pharmaceuticals

Alzheon
alzheon.com

Regenerative Bio
regen-bio.us

Aristea Therapeutics
Companies similar to Aeovian Pharmaceuticals include Azevan Pharmaceuticals, Avalyn Pharma, Aria Pharmaceuticals and Abvc Biopharma.
Aeovian Pharmaceuticals was founded in 2012.
Aeovian Pharmaceuticals' headquarters is located in San Francisco, CA, US.
Aeovian Pharmaceuticals' most recent funding round was for $37M (USD) in October 2019.
As of Oct 3, 2019, Aeovian Pharmaceuticals has raised a total of $37.8M (USD).
Aeovian Pharmaceuticals has 13 employees as of Feb 5, 2024.